Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback